Although childhood leukemia is considered a rare disease, it is the most common cancer that affects children. The hospital’s leukemia studies have pioneered the way the world treats childhood leukemia. St. Jude also pioneered outpatient clinical trials for children with leukemia, reducing the need for inpatient stays.
The following leukemia experts are available to offer credible information, hands-on expertise and clinical insight on childhood leukemia.
To schedule interviews or speak with one of our experts, email firstname.lastname@example.org or contact one of our media relations staff.
Childhood Leukemia Experts
Sima Jeha, MD, is faculty in the departments of Oncology as well as Global Pediatric Medicine at St. Jude. In 2018, through the alliance of St. Jude Global, she and her Lebanese colleagues found that effective pediatric cancer treatment is possible in the midst of the refugee crisis caused by the war in Syria. She can be contacted about her research interests in developmental therapeutics, protocol development and clinical investigations in leukemia, relapsed and refractory leukemia, and leukemia in the adolescent and young adult.
Charles Mullighan, MBBS (Hons), MSc, MD, is the St. Jude Comprehensive Cancer Center deputy director and the St. Jude Biorepository medical director. His research focuses on using integrated genomic, epigenomic and experimental approaches to understand acute lymphoblastic leukemia (ALL) and related disorders. He has led landmark studies that have defined the inherited and somatic genetic alterations in ALL. Mullighan can provide considerable insight into findings that have led to genomically informed diagnostic approaches and multiple clinical trials testing precision medicine approaches.
Ching-Hon Pui, MD, is the Oncology chair at St. Jude Children's Research Hospital and is director of the China Region for St. Jude Global. One focus of his research is improving combination chemotherapy to increase cure rates while improving the quality of life during treatment and in survivorship. He advocates for avoiding bone marrow transplantation and subsequent radiation, if possible. Other research interests include evaluating the efficacy of novel anti-leukemic drugs or new therapeutic strategies, and applying molecular genetic, pharmacologic and immunologic discoveries to clinical problems.
Jeffrey Rubnitz, MD, PhD, is the Leukemia/Lymphoma Division chief at St. Jude Children's Research Hospital. He is interested in developing new strategies for the treatment of acute myeloid leukemia (AML). Rubnitz can provide information based on leading several clinical trials exploring novel therapies for certain high-risk groups, as well as studies of minimal residual disease and genome-wide analysis in AML.